Women can lose up to 20 percent of their bone density in the five to seven years after menopause. Most do not know this is happening until something breaks. Here is what the research actually shows about prevention, and how bioidentical hormone therapy and DEXA tracking change the long-term outcome.
There is a moment in our Sandy, Utah office that I have stopped trying to brace for. A woman in her late fifties or sixties comes in for a wellness visit. She feels fine. She is active. She eats well. And then her first DEXA scan shows osteopenia, sometimes outright osteoporosis, sometimes a spine T-score that suggests she has already had a vertebral compression fracture she did not even notice. The bone loss had been happening quietly for years. Nobody was watching.
This is the version of menopause that does not make it into the brochures. Hot flashes, mood changes, sleep problems, sure. Those are the symptoms women come in talking about. The bone loss happens in silence and only announces itself when something breaks.
Here is the part of the story most women have never been told: the first five to seven years after your last menstrual period are when this damage happens. Not at 70. Not at 75. In your early to mid fifties, while you are still going to spin class and lifting your grandkids.
Key Takeaways
- Women can lose up to 20 percent of their bone density in the first five to seven years after menopause, according to the Cleveland Clinic, Mass General Brigham, and the Bone Health and Osteoporosis Foundation. The rate during that window can hit 3 to 5 percent per year before slowing down.
- One in two postmenopausal women will experience a major osteoporotic fracture in her lifetime, per the Endocrine Society. Hip fractures carry a 22.8 percent one-year mortality rate in women aged 65 and older, according to a Kaiser Permanente study of 13,550 patients.
- Estrogen is the primary signal that keeps bone formation in balance with bone breakdown. When estrogen drops at menopause, that balance tips, and the bone you have spent your entire life building starts to come off faster than your body can replace it.
- Hormone therapy, including bioidentical hormone replacement therapy (BHRT), is one of the most effective tools we have for preventing this loss. The data is strong enough that the Endocrine Society and the Menopause Society both list HRT as an approved first-line option for prevention of postmenopausal osteoporosis.
- A DEXA scan is the only way to know what is actually happening to your bones. Most women have never had one. At Revitalize Medical Solutions in Sandy, Utah, every patient on our hormone optimization program gets a baseline DEXA and follow-up scans to confirm the protocol is working.
Contents
1. What happens to bones during the first five years of menopause
Your bones are not the static structural beams most people picture. Bone is a living, constantly remodeling tissue. Osteoclasts (cells that break down old bone) and osteoblasts (cells that build new bone) work in continuous balance throughout your life. Estrogen is the primary signal keeping that balance tipped toward formation rather than breakdown.
During the perimenopause transition and the years following your final menstrual period, estrogen drops dramatically. Plasma estradiol levels in postmenopausal women fall to less than ten percent of premenopausal values. The signal that has been keeping your bones intact since adolescence is suddenly gone. The osteoclasts keep doing their job. The osteoblasts slow down. The balance tips, and bone density starts coming off faster than your body can rebuild it.
How much faster? The annual rate of bone mineral density loss during the rapid postmenopausal phase is typically 1 to 2 percent per year, with some women losing 3 to 5 percent per year. The Cleveland Clinic states that women can lose up to 20 percent of their total bone density within five years of starting menopause. The Bone Health and Osteoporosis Foundation puts the timeline at five to seven years for that 20 percent loss. After this rapid phase, the rate slows to roughly 0.5 to 1 percent per year, similar to what is seen in older men.
Translation: the damage is concentrated in a narrow window. By the time you are 60 and someone is finally suggesting a bone density scan, the most aggressive phase of loss has already happened.
Key insight: The first five to seven years after your last menstrual period are the most critical window for bone preservation in a woman’s life. By the time symptoms or fractures appear, decades of bone density may already be gone.
2. Why estrogen matters so much for bone
Estrogen does several things at once for bone tissue. It slows down osteoclast activity, the cells that break down bone. It supports osteoblast activity, the cells that build new bone. It improves calcium absorption in the gut. It influences how your kidneys handle calcium. And it contributes to the structural quality of bone, not just the quantity.
When estrogen drops, all of those effects unwind at the same time. The Hormonal Changes During Menopause and Their Impact on Bone Health study published in 2025 found that women beyond five years of menopause had osteopenia prevalence of 49 percent and osteoporosis prevalence of 25 percent. One in four women five years past menopause already has osteoporosis.
Progesterone and testosterone, both of which also drop during menopause, contribute to this picture too. Progesterone helps stimulate bone formation. Testosterone supports bone density indirectly by increasing muscle mass, which loads the bones and signals them to stay strong. When all three of these hormones decline together, the protective effect on bone disappears from multiple directions at once.
This is why bone loss is not just an osteoporosis problem to manage when it appears. It is a hormonal problem that begins long before the diagnosis.
“By the time osteoporosis shows up on a scan, the underlying hormonal change has been driving the loss for years. That is what we are trying to interrupt earlier.” Nicole Kelly, PA-C, Medical Director
3. What the research says about hormone therapy and bone density
The evidence that hormone therapy prevents postmenopausal bone loss is among the strongest in all of menopause medicine. The original Women’s Health Initiative, despite the headlines about its cardiovascular findings, actually showed a 33 percent reduction in hip fractures among women on combined estrogen and progestin therapy. That is one of the largest randomized trial findings ever produced for any osteoporosis intervention.
The Endocrine Society’s current clinical practice guidelines list hormone therapy as a first-line option for the prevention of osteoporosis in postmenopausal women under age 60 or within ten years of menopause onset. The Menopause Society agrees. Mass General Brigham, in their recent patient education materials on menopause and osteoporosis, states plainly that hormone therapy is a safe and effective treatment to prevent osteoporosis in women who are at risk.
In November 2025, the FDA acted on this accumulated evidence in a significant way. Following a comprehensive scientific review, an expert panel, and a public comment period, the agency removed the longstanding black box warnings on cardiovascular disease, breast cancer, and probable dementia from menopause hormone therapy products. FDA Commissioner Marty Makary, announcing the decision in JAMA, stated the original warnings were based on outdated science and had discouraged appropriate use of hormone therapy. The endometrial cancer warning for estrogen-alone products remains in place, as it should. For the first time in more than two decades, providers and patients can have a clear-eyed conversation about hormone therapy without that boxed warning sitting in the middle of the consultation.
Key insight: The FDA’s November 2025 removal of black box warnings on menopause hormone therapy reflects more than twenty years of accumulated evidence that the original warnings overstated risk and discouraged appropriate use. For women in the bone health window, the regulatory message has shifted from caution-by-default to individualized risk-benefit discussion.
More recent research has examined the question of timing. A prospective study published in Menopause found that women who stopped hormone therapy had a significantly greater risk of hip fracture within two years of cessation than women who stayed on therapy. The protective effect on bone does not extend much past the day a woman stops taking it. This is why the conversation about hormone therapy needs to start early and continue intentionally, not be left to whenever a fracture finally happens.
On the bioidentical hormone replacement therapy (BHRT) question specifically: bioidentical hormones, meaning hormones structurally identical to the ones your body produces naturally, deliver the same bone-protective effects as conventional synthetic hormone therapy. The mechanism is the same. Estradiol is estradiol, regardless of whether it came from a horse or a yam. What changes with bioidentical formulations is the side effect profile and the ability to dose more precisely to a patient’s actual hormone levels rather than to a one-size-fits-all preparation.
Key insight: Hormone therapy started in the first ten years after menopause prevents bone loss. Hormone therapy started after age 60, or more than ten years past menopause, does not deliver the same benefit. Timing matters enormously.
4. What this looks like in our Sandy, Utah office
Every patient on our hormone optimization program at our Sandy clinic gets a baseline DEXA scan. We do this because you cannot manage what you do not measure. A patient who has been on hormone therapy for a year should not have to wonder whether her bones are responding to treatment. The scan tells us, and the scan tells her. Our Female Balance and Beauty program is built around this principle of measured, individualized hormone optimization with DEXA-verified outcomes.
Most clinics that prescribe hormone therapy do not run DEXA scans. Most clinics that run DEXA scans do not prescribe hormone therapy. The two have historically lived in separate professional silos. We do both because the data only matters when it is in the same hands as the treatment plan.
The clinical pattern we see again and again: women who start hormone optimization in their late forties or early fifties, before significant bone loss has occurred, maintain or improve their bone density into their sixties and seventies. Women who start in their sixties after a fracture, or after a DEXA scan finally catches the loss, can still slow the progression but cannot fully reverse what has already been lost.
A patient story from our Sandy office (details adjusted to protect privacy): a postmenopausal woman in her early fifties came to us for comprehensive weight management after struggling with menopausal weight gain. We started her on hormone optimization first, then layered in DEXA tracking, protein guidance, strength training, and a GLP-1 medication when clinically indicated. Over the next year and a half she lost more than 55 pounds. Here is the part most people would not expect: her bone mineral density actually increased by 1.5 percent during that same period, a statistically significant gain by the standard DEXA threshold. Her T-score moved from 0.2 to 0.4. This is not what usually happens during dramatic weight loss in a postmenopausal woman. Most patients on GLP-1 medications without hormone optimization lose bone alongside the fat and muscle. With hormone optimization layered in, hers improved. This is one example, not a guaranteed outcome, but it is the kind of outcome that becomes possible when the protocol is built right. The full story of her weight loss and muscle preservation is covered in our companion article on GLP-1 medications and menopause.
5. Questions to ask your provider before menopause hits
If you are perimenopausal or recently postmenopausal, these are the questions that matter most for your bones. Ask them before symptoms appear, not after.
Have I had a baseline DEXA scan?
Most women have not, and most providers will not order one until something goes wrong. This is backwards. A baseline scan during perimenopause or early menopause gives you and your provider the data needed to monitor changes over time. Without it, you are flying blind.
Am I a candidate for hormone therapy?
Most healthy women under 60 or within ten years of menopause onset are candidates for hormone therapy, especially when bone protection is a goal. The contraindications (active or recent breast cancer, certain blood clotting disorders, severe liver disease) are specific and well defined. Bioidentical hormone optimization is something we evaluate individually for every patient, based on her labs, symptoms, family history, and goals.
What is my protein and strength training plan?
Bone responds to mechanical loading. Resistance training and adequate protein intake (typically 1.2 to 1.6 grams per kilogram of body weight per day for postmenopausal women) are foundational, with or without hormone therapy. If your provider has not discussed this with you, you are missing a core piece of the picture.
Are we monitoring with follow-up scans?
A baseline is the start. Follow-up scans at appropriate intervals confirm whether the protocol is working. If your provider does not have a plan for follow-up DEXA scans, you have a treatment plan without a feedback loop.
Key insight: A real postmenopausal bone health plan answers four questions. Baseline DEXA scan. Candidacy for hormone therapy. Protein and strength training. Follow-up monitoring. If any of those four are missing, you are not getting comprehensive care.
6. Why we wrote this
We wrote this article because the standard pathway for women’s bone health in the United States is to wait until something breaks. That is not a pathway, it is a failure. The first DEXA scan most women ever receive is the one ordered after a hip fracture, when the cost of the loss is already paid.
In our Sandy office, we see this pattern play out from the other direction. Women who started hormone optimization in their late forties or early fifties walk through their sixties and seventies with intact bone density and the strength to keep doing the things they love. Women who skipped that window face a much harder rebuild, and sometimes a rebuild that is not fully possible.
“We have done thousands of baseline DEXA scans over the years. I am personally appalled at the number of postmenopausal women who come in with severe bone loss that our providers consistently prevent through hormone optimization. Typical medical care tells women to wait until they already have osteopenia before treating it, and the first-line treatments carry side effects bad enough that roughly half of women stop taking them within a year. That is an unfortunate outcome given what bone loss does to women’s health.” Cale Bybee, COO, Revitalize Medical Solutions · Licensed Bone Densitometry Equipment Operator (Utah)
The five-to-seven-year window after menopause is not optional. The biology is the biology. You either act inside it or you live with the consequences. If you are in the Salt Lake City or Sandy area and you want to know what is actually happening to your bones, we would like to help.
The Bottom Line
Women lose up to 20 percent of their bone density in the first five to seven years after menopause. One in two postmenopausal women will experience a major fracture in her lifetime, and hip fractures carry roughly a 22.8 percent one-year mortality rate in older women. The biology is driven by the loss of estrogen, progesterone, and testosterone, all of which support bone maintenance. Hormone therapy started inside the first ten years of menopause prevents most of this loss. DEXA scans are the only way to know whether your treatment is working. A complete plan includes a baseline scan, individualized hormone optimization (bioidentical when appropriate), protein and strength training, and follow-up monitoring. The window for prevention is narrow. It is also predictable, which means it is plannable.
Frequently Asked Questions
How much bone density do women actually lose after menopause?
Women can lose up to 20 percent of their bone mineral density in the first five to seven years after menopause, per the Cleveland Clinic and the Bone Health and Osteoporosis Foundation. The annual rate during this window is typically 1 to 2 percent, with some women losing as much as 3 to 5 percent per year. After this rapid phase, the rate slows to about 0.5 to 1 percent per year for the rest of life.
Is it too late if I am already 60 and already past menopause?
It depends on how far past menopause you are and what your current bone density looks like. Hormone therapy started within ten years of menopause onset still delivers meaningful bone protection. Beyond that window, the bone-specific benefit drops significantly, though other osteoporosis treatments (bisphosphonates, denosumab, anabolic agents) can still slow further loss. A DEXA scan and a clinical evaluation tell us where you actually stand and what is still possible.
Is BHRT (bioidentical hormone therapy) actually different from regular HRT for bones?
The bone protective mechanism is the same. Estradiol is the molecule that protects bone, regardless of whether it is delivered as a bioidentical preparation or a conventional synthetic formulation. What changes with bioidentical hormone therapy is the ability to dose more precisely to a patient’s individual labs, the side effect profile, and in many cases the route of administration (transdermal versus oral). All of these factors affect tolerability and adherence, which matter clinically because the bone benefit only continues as long as the woman stays on therapy.
Does the FDA still warn against hormone therapy for menopause?
No, not in the same way. On November 10, 2025, the FDA announced it was removing the longstanding black box warnings on cardiovascular disease, breast cancer, and probable dementia from menopause hormone therapy products. The agency stated the original warnings, in place for more than 20 years, were based on outdated science and had discouraged appropriate use of hormone therapy. The endometrial cancer warning for estrogen-alone products remains in place. For most women within 10 years of menopause onset, hormone therapy now carries no boxed warning and is recognized as an appropriate first-line option for symptom management and osteoporosis prevention.
What if I do not want to be on hormone therapy?
Hormone therapy is not the only path. Adequate calcium and vitamin D, resistance training, weight-bearing exercise, and avoiding smoking and excess alcohol all contribute to bone maintenance. For women with established osteoporosis or who cannot use hormones, FDA-approved medications including bisphosphonates, denosumab, and anabolic agents (teriparatide, romosozumab) are clinically effective. The right answer depends on your individual risk profile, your bone density numbers, your other health conditions, and your preferences. The goal of the consultation is to figure out which combination fits your situation, not to push any single option.
How often should I have a DEXA scan?
For women starting hormone therapy, we recommend a baseline scan, a follow-up scan at 12 to 18 months to confirm response, and then every 2 to 3 years depending on the stability of the numbers. Women with normal bone density and no risk factors may need scans less frequently. Women with osteopenia or osteoporosis, or who are on medications that affect bone, may need more frequent monitoring. This is a conversation to have with your provider based on your specific clinical picture.
Does GLP-1 weight loss medication affect bone density?
Yes, and this is something most patients are not warned about. Dramatic weight loss, including weight loss driven by GLP-1 medications like semaglutide and tirzepatide, is associated with reductions in bone density, particularly at the hip and spine. The mechanism is partly mechanical (less weight loading the bones) and partly metabolic. This is one of the reasons we built our comprehensive weight management protocol the way we did, and it is why DEXA tracking matters even more during GLP-1 therapy in postmenopausal women. We cover this in detail in our companion article on GLP-1 medications and menopause.
Can I increase bone density once I have lost it?
In some cases, yes. The anabolic osteoporosis medications (teriparatide and romosozumab) can build new bone, not just slow the loss. Hormone therapy started early enough can stabilize and sometimes modestly improve density. Strength training combined with adequate protein and vitamin D can also produce small gains over time. What is not realistic in most cases is fully reversing significant osteoporotic loss in a postmenopausal woman without intervention. Which is why the prevention conversation, started early, matters so much more than the rescue conversation started late.
Why does Revitalize do DEXA scans in-house?
Because the data and the treatment plan need to live in the same place. A DEXA scan ordered at one facility and a hormone prescription written at another results in two siloed pieces of information that nobody is integrating. Our scanner, our provider team, and our clinical decisions all share the same patient record. When your bone density changes, we see it, we respond to it, and we adjust the protocol. That feedback loop is the differentiator between a treatment plan and a guess.
How does Revitalize approach BHRT differently?
Three things. First, every BHRT patient gets a baseline DEXA, follow-up DEXA scans, and comprehensive lab work, so dosing is based on actual data rather than symptom check-ins alone. Second, we dose to the individual woman rather than to a population average, which means smaller adjustments more often as her labs and symptoms evolve. Third, BHRT lives inside a comprehensive program that also includes nutrition, strength training, and where indicated, GLP-1 medications and other tools, rather than being prescribed in isolation. For more about how we work with patients, see our patient FAQs.
Have you ever had a baseline DEXA scan?
Comprehensive hormone optimization with DEXA-verified bone health, individually dosed BHRT, and a structured follow-up plan. At our Sandy, Utah clinic. The full program, not just a prescription.
SCHEDULE A FREE CONSULTATION AT OUR SANDY, UTAH CLINIC →
References
FDA. Requests Labeling Changes Related to Safety Information to Clarify the Benefit/Risk Considerations for Menopausal Hormone Therapies. November 10, 2025. (Makary MA, Nguyen CP, Hoeg TB, Tidmarsh GF. Updated Labeling for Menopausal Hormone Therapy. JAMA. 2025 Nov 10. doi: 10.1001/jama.2025.22259.)
Harvard Health. FDA removes menopause hormone therapy black box warnings. November 13, 2025. https://www.health.harvard.edu/womens-health/fda-removes-menopause-hormone-therapy-black-box-warnings
Cleveland Clinic Health. What To Know About Menopause and Bone Loss. (Pelin Batur, MD). https://health.clevelandclinic.org/osteoporosis-and-menopause
Bone Health and Osteoporosis Foundation. What Women Need to Know. https://www.bonehealthandosteoporosis.org/preventing-fractures/general-facts/what-women-need-to-know/
Mass General Brigham. Menopause and Osteoporosis. (Eva Chou, MD). https://www.massgeneralbrigham.org/en/about/newsroom/articles/menopause-and-osteoporosis
Trends in Mortality Following Hip Fracture in Older Women. Kaiser Permanente. American Journal of Managed Care. (1-year mortality of 22.8% in 13,550 postmenopausal women aged 65+). https://www.ajmc.com/view/trends-in-mortality-following-hip-fracture-in-older-women
Hip Fracture in Postmenopausal Women After Cessation of Hormone Therapy. Menopause Journal / PMC. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3511047/
Hormonal Changes During Menopause and Their Impact on Bone Health: Insights from Orthopedic and Reproductive Medicine. PMC. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12464279/
Hip Fracture Incidence in Relation to Age, Menopausal Status, and Age at Menopause: Prospective Analysis. PLOS Medicine. https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1000181
Reviewed by Nicole Kelly, PA-C · Medical Director, Revitalize Medical Solutions · Sandy, Utah · Contributing voice from Cale Bybee, COO and Utah-licensed Bone Densitometry Equipment Operator · All clinical claims verified prior to publication · Patient case study presented with details adjusted to protect privacy · Document version 1.1
